etrumadenant + sacituzumab govitecan + zimberelimab

This is an investigational combination therapy comprising three agents with distinct mechanisms of action, under evaluation for the treatment of advanced solid tumors, particularly metastatic colorectal cancer.

• Etrumadenant is a small molecule dual antagonist of adenosine A2a and A2b receptors, designed to block adenosine-mediated immunosuppression in the tumor microenvironment and restore antitumor immune cell activity.
• Sacituzumab govitecan is an antibody-drug conjugate targeting Trop-2, delivering the cytotoxic payload SN-38 to Trop‑2–expressing cancer cells. It induces direct tumor cell death via DNA damage.
• Zimberelimab is a monoclonal antibody that inhibits PD‑1, thereby enhancing T-cell–mediated antitumor immunity.

The combination aims to synergistically enhance immune-mediated tumor killing by simultaneously blocking immunosuppressive pathways and directly targeting tumor cells.